Definitive Contract 75N93022C00037
Award Date
8/30/22
Potential Completion Date
8/29/24
Potential Value
$600K
Federal Agency
National Institute of Allergy and Infectious Diseases
Awardee
Adjuvax LLC
Ultimate Awardee
Not listed
Federal Contract Vehicle
Set-Aside Type
Total Small Business
Extent Competed
Full and Open Competition after exclusion of sources
Major Defense Program
Not listed
Pricing Type
Firm Fixed Price
Place of Performance
Birmingham, AL 35226, USA
Solicitation Procedures
Negotiated Proposal / Quote
Number Of Offers Received
4
Legislative Mandate
Employment Eligibility Verification
National Interest Action
Not listed
Research Type
SBIR Program Phase I Action
Primary Consortia Member
Not listed
Similar Awards
This definitive contract was awarded by the National Institutes of Health's National Institute of Allergy and Infectious Diseases to Celdara Medical of Lebanon, New Hampshire. With a value of $599,977, the firm fixed price contract supports research under Solicitation Number NIH-CDC-SBIR-2019 in adjuvant development for vaccines against infectious or immune-mediated diseases. Specifically, the prime contractor will conduct work requested under Topic 081 of the solicitation, which sought small...
This definitive contract from the Department of Health and Human Services' National Institutes of Health and National Institute of Allergy and Infectious Diseases awards Inimmune Corporation $1.99 million to develop a Synthetic Adjuvant System. The contract is a result of the agency's SBIR Phase II solicitation seeking proposals for research and development to advance NIH and CDC missions, including alternatives to cell culture materials and cancer immunotherapy manufacturing. Placed in...
The Department of Health and Human Services (HHS) National Institutes of Health (NIH) National Institute of Allergy and Infectious Diseases (NIAID) awarded a firm fixed price purchase order contract to Advanced Bioadjuvants, LLC, a self-certified small disadvantaged business. The contract is for license fees related to the Adjuplex trademark, patents, and trade secret manufacturing process, which NIAID will use to combine with human vaccines for clinical trials. The contract has a 12-month...
This is a Phase I Small Business Innovation Research (SBIR) contract awarded by the National Institutes of Health's (NIH) National Institute of Allergy and Infectious Diseases to Teichos Laboratories, LLC, a small business located in West Lafayette, IN. The $300,000 firm fixed price contract is for research on a novel TLR2 agonist-aluminum combination adjuvant to improve the quality and duration of the immune response. This SBIR contract was awarded under a solicitation that sought innovative...
The Department of Health and Human Services, National Institutes of Health, National Institute of Allergy and Infectious Diseases awarded a $4,148,210.00 Firm Fixed Price Definitive Contract to Metaclipse Therapeutics Corp, a self-certified small disadvantaged business, for the development of membrane-anchored cytokines as novel vaccine adjuvants for the elderly. This contract, which has a completion date of December 31, 2022, is part of the agency's "DEVELOPMENT OF MEMBRANE ANCHORED...
This is a $300,000 Firm Fixed Price contract awarded by the Department of Health and Human Services' National Institutes of Health (NIH) National Institute of Allergy and Infectious Diseases to Vitruvian Bio, LLC, a small disadvantaged woman-owned business. The contract is for a Small Business Innovation Research (SBIR) Phase I project to be completed by June 30, 2023. The award is associated with a larger SBIR solicitation that sought innovative research proposals from small businesses to...
This is a cost-type definitive contract awarded by the National Institute of Allergy and Infectious Diseases (NIAID), a civilian agency, to Virovax LLC, a minority-owned limited liability company, for an Adjuvant Development Program. The contract has a ceiling value of $9,273,316.19 and a period of performance through September 29, 2025. The contract was awarded on September 30, 2018 and does not utilize a set-aside designation. As NIAID is the funding agency, this award is likely supporting...
The National Institute of Allergy and Infectious Diseases (NIAID), a civilian agency within the Department of Health and Human Services, has awarded a five-year, $9,189,961.00 definitive contract to Institut De Formulation DES Vaccins (Ch) SA, operating as Vaccine Formulation Institute (Ch) LTD, for the Vaccine Adjuvant Discovery Program. This program aims to identify and characterize novel, effective, and safe vaccine adjuvants through a multi-step research process, including high-throughput...
This definitive contract from the Department of Health and Human Services' National Institutes of Health and National Institute of Allergy and Infectious Diseases (HHS-NIH-NIAID) is valued at $600,000 to Antagen Biosciences Inc., doing business as Antagen Pharmaceuticals, for work in Boston, MA from September 2020 through August 2022. The contract was awarded under the Small Business Innovation Research (SBIR) program's total small business set-aside solicitation seeking proposals on topics...
This firm-fixed-price SBIR Phase I contract was awarded by the Department of Health and Human Services' National Institute of Allergy and Infectious Diseases to HDT Bio Corp, a for-profit biopharmaceutical company. The $599,629 contract funds the "Rational Development of a Combination Nanoparticle Adjuvant for Influenza", which involves research and development of novel adjuvants and other medical countermeasures. HDT Bio Corp has previously served as a prime contractor on other HHS...